Innoviva is trading 8.2% up at $23.00 in pre-market on November 5 after its November 4 results, where adjusted earnings beat estimates. - Revenue was $106.1 million, below estimates; adjusted earnings were $0.50 per share versus the Zacks consensus of $0.49. - U.S. product sales rose 45% to $43.3 million; management reaffirmed 2026 sales guidance. - Net loss was $73.9 million, primarily reflecting lower investment fair values. Biotech stocks rose 2.08% pre-market amid a broader sector rally, which may also support the move.